A detailed history of Janney Montgomery Scott LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Janney Montgomery Scott LLC holds 127,425 shares of VRTX stock, worth $64 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
127,425
Previous 129,809 1.84%
Holding current value
$64 Million
Previous $60.8 Million 2.6%
% of portfolio
0.17%
Previous 0.19%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

SELL
$460.0 - $505.78 $1.1 Million - $1.21 Million
-2,384 Reduced 1.84%
127,425 $59.3 Million
Q2 2024

Jul 25, 2024

BUY
$392.81 - $485.53 $2.97 Million - $3.67 Million
7,553 Added 6.18%
129,809 $60.8 Million
Q1 2024

May 01, 2024

SELL
$407.69 - $446.08 $2.49 Million - $2.73 Million
-6,114 Reduced 4.76%
122,256 $51.1 Million
Q4 2023

Feb 07, 2024

BUY
$343.0 - $410.68 $2.46 Million - $2.95 Million
7,176 Added 5.92%
128,370 $52.2 Million
Q3 2023

Nov 08, 2023

SELL
$338.18 - $362.46 $1.63 Million - $1.75 Million
-4,819 Reduced 3.82%
121,194 $42.1 Million
Q2 2023

Jul 26, 2023

BUY
$314.42 - $351.91 $263,483 - $294,900
838 Added 0.67%
126,013 $44.3 Million
Q1 2023

Apr 28, 2023

SELL
$283.23 - $323.1 $965,531 - $1.1 Million
-3,409 Reduced 2.65%
125,175 $39.4 Million
Q4 2022

Feb 01, 2023

BUY
$285.76 - $321.48 $6.07 Million - $6.83 Million
21,258 Added 19.81%
128,584 $37.1 Million
Q3 2022

Oct 25, 2022

BUY
$273.83 - $305.53 $3.42 Million - $3.82 Million
12,506 Added 13.19%
107,326 $31.1 Million
Q2 2022

Aug 03, 2022

SELL
$234.96 - $292.55 $2.84 Million - $3.54 Million
-12,091 Reduced 11.31%
94,820 $26.3 Million
Q1 2022

May 04, 2022

BUY
$221.42 - $260.97 $11.5 Million - $13.6 Million
52,024 Added 94.78%
106,911 $27.9 Million
Q4 2021

Jan 27, 2022

BUY
$177.01 - $223.45 $431,727 - $544,994
2,439 Added 4.65%
54,887 $12.1 Million
Q3 2021

Oct 29, 2021

BUY
$181.39 - $202.99 $352,803 - $394,815
1,945 Added 3.85%
52,448 $9.51 Million
Q2 2021

Jul 26, 2021

SELL
$187.49 - $221.1 $1.15 Million - $1.36 Million
-6,160 Reduced 10.87%
50,503 $10.2 Million
Q1 2021

Apr 27, 2021

BUY
$207.02 - $241.31 $494,363 - $576,248
2,388 Added 4.4%
56,663 $12.2 Million
Q4 2020

Jan 25, 2021

SELL
$207.01 - $276.09 $12.9 Million - $17.2 Million
-62,173 Reduced 53.39%
54,275 $12.8 Million
Q3 2020

Nov 06, 2020

BUY
$255.65 - $303.1 $2.67 Million - $3.16 Million
10,438 Added 9.85%
116,448 $31.7 Million
Q2 2020

Jul 23, 2020

BUY
$225.48 - $295.8 $3.38 Million - $4.43 Million
14,990 Added 16.47%
106,010 $30.8 Million
Q1 2020

Apr 30, 2020

BUY
$199.77 - $247.81 $4.23 Million - $5.25 Million
21,183 Added 30.33%
91,020 $21.7 Million
Q4 2019

Jan 21, 2020

BUY
$166.71 - $223.91 $5.54 Million - $7.44 Million
33,221 Added 90.73%
69,837 $15.3 Million
Q3 2019

Oct 29, 2019

BUY
$166.23 - $187.09 $261,479 - $294,292
1,573 Added 4.49%
36,616 $6.2 Million
Q2 2019

Jul 29, 2019

SELL
$164.61 - $190.37 $299,096 - $345,902
-1,817 Reduced 4.93%
35,043 $6.43 Million
Q1 2019

Apr 30, 2019

SELL
$163.73 - $194.7 $494,300 - $587,799
-3,019 Reduced 7.57%
36,860 $6.78 Million
Q4 2018

Feb 01, 2019

SELL
$151.91 - $192.21 $552,800 - $699,452
-3,639 Reduced 8.36%
39,879 $6.61 Million
Q3 2018

Nov 05, 2018

BUY
$167.73 - $192.74 $1.36 Million - $1.56 Million
8,117 Added 22.93%
43,518 $8.39 Million
Q2 2018

Jul 24, 2018

SELL
$145.72 - $169.96 $192,933 - $225,027
-1,324 Reduced 3.61%
35,401 $6.02 Million
Q1 2018

Apr 19, 2018

BUY
$151.6 - $177.13 $797,719 - $932,058
5,262 Added 16.72%
36,725 $5.99 Million
Q4 2017

Feb 14, 2018

BUY
$137.28 - $155.55 $72,346 - $81,974
527 Added 1.7%
31,463 $4.72 Million
Q3 2017

Nov 15, 2017

BUY
$148.13 - $162.24 $4.58 Million - $5.02 Million
30,936
30,936 $4.7 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Janney Montgomery Scott LLC Portfolio

Follow Janney Montgomery Scott LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janney Montgomery Scott LLC, based on Form 13F filings with the SEC.

News

Stay updated on Janney Montgomery Scott LLC with notifications on news.